Daiichi Sankyo aims to transform its antibody-drug conjugate leadership into a top global oncology standing. In a new five-year business plan unveiled Monday, the Japanese pharma outlined a roadmap to become a global top five oncology player by 2035, plus a major $1.3 billion cost optimization initiative.
- Home |
- Daiichi Sankyo targets global top 5 oncology rank by 2035, $1.3B efficiency drive in new 5-year plan
Daiichi Sankyo targets global top 5 oncology rank by 2035, $1.3B efficiency drive in new 5-year plan
- May 11, 2026
Recent Posts
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
- Cenovus to build oil sands business via Athabasca acquisition
- Centalion acquires Haynesville gas assets from Silver Hill
